Magnetar Financial’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Magnetar Financial’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-254,570	Closed	-$323K	–	1555
2021 Q3	$323K	Hold	254,570	–	–	﹤0.01%	995
2021 Q2	$440	Hold	254,570	–	–	﹤0.01%	918
2021 Q1	$305K	Hold	254,570	–	–	﹤0.01%	924
2020 Q4	$496K	Buy	+254,570	New	+$439K	0.01%	562

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Magnetar Financial's STLNW Position: Q4 2021 in Review

Magnetar Financial sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 254,570 shares — an estimated $323K sold.

Magnetar Financial first reported a position in STLNW in Q4 2020 and held it in 4 quarters. The position peaked at $496K in Q4 2020. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

Magnetar Financial reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
Magnetar Financial sold 254,570 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $323K.
Magnetar Financial first reported a position in Starling Oncology, Inc. Warrant in Q4 2020 and held it in 4 quarters.
Magnetar Financial's Starling Oncology, Inc. Warrant position peaked at $496K in Q4 2020.
20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on Magnetar Financial's 13F filing for Q4 2021, filed 14 Feb 2022.